Review
Non-competitive antagonists of excitatory amino acid receptors

https://doi.org/10.1016/0166-2236(87)90176-7Get rights and content

Abstract

Non-competitive antagonists have become important tools for investigating the basic mechanisms of NMDA receptor function. Such compounds (e.g. MK-801, PCP) are thought to act at the level of the NMDA receptor-associated ion channel and many show a marked use-dependence in their antagonist properties. Little information is available concerning selective non-competitive antagonists of quisqualate or kainate receptors. A number of structurally diverse compounds act as non-competitive antagonists of glutamate receptors at invertebrate neuromuscular junctions, although it remains to be determined whether these compounds have effects at excitatory amino acid receptors in the mammalian CNS. The ability of the non-competitive NMDA receptor antagonists to penetrate the brain following systemic administration, and the use-dependency of their antagonism may confer distinct therapeutic advantages in the treatment of neurological disorders where an overstimulation of NMDA receptors is thought to occur (such as in epilepsy or cerebral ischaemia).

References (45)

  • D. Martin et al.

    Neuropharmacology

    (1985)
  • C.R. Honey et al.

    Neurosci. Lett.

    (1985)
  • D.T. Manallack et al.

    Trends Pharmacol. Sci.

    (1986)
  • P. Loo et al.

    Eur. J. Pharmacol.

    (1986)
  • J. Vignon et al.

    Eur. J. Pharmacol.

    (1982)
  • J.L. Barker

    Brain Res.

    (1975)
  • V.I. Teichberg et al.

    Brain Res.

    (1984)
  • Z. Miljkovic et al.

    Brain. Res.

    (1986)
  • H. Shinozaki et al.

    Brain Res.

    (1986)
  • M. Idriss et al.

    FEBS Lett.

    (1985)
  • C. Franke et al.

    Neurosci. Lett.

    (1983)
  • D. Lodge et al.
  • E.H.F. Wong et al.
  • N.L. Harrison et al.

    Br. J. Pharmacol.

    (1985)
  • J.F. MacDonald et al.
  • J.A. Kemp et al.

    Br. J. Pharmacol.

    (1986)
  • W.F. Maragos et al.

    Eur. J. Pharmacol.

    (1986)
  • N.G. Bowery et al.

    Br. J. Pharmacol.

    (1986)
  • Fagg, G. E. Neurosci. Lett. (in...
  • Foster, A. C. and Wong, E. H. F. Br. J. Pharmacol. (in...
  • J-P. Changeux et al.

    Science

    (1984)
  • E.X. Albuquerque et al.

    Mol. Pharmacol.

    (1980)
  • Cited by (490)

    • Recent Applications of Selected Name Reactions in the Total Synthesis of Alkaloids

      2021, Recent Applications of Selected Name Reactions in the Total Synthesis of Alkaloids
    • NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

      2016, Experimental Neurology
      Citation Excerpt :

      This result supports the suggestion that the action of NBQX (AMPA/KA receptor antagonist) is through the KA receptors as opposed to the AMPA receptors in the TMEV-induce seizure model. MK 801 has been shown to be an antagonist of the NMDA receptor ion channel (Kemp et al., 1987; Wong et al., 1986). MK 801 treatment was found to protect hippocampal neurons against ischemic neuronal necrosis in the rat (Rod and Auer, 1989), and to protect hippocampal CA1 and CA3 neurons against damage in a rat model of mTLE (KA-induced SE), however no antiepileptogenic effects were evident when MK 801 was administered after KA-induced SE (Brandt et al., 2003).

    • NMDA receptor subtypes: Structure, function and therapeutics

      2008, Current Anaesthesia and Critical Care
    • Apnea promotes glutamate-induced excitotoxicity in hippocampal neurons

      2007, Brain Research
      Citation Excerpt :

      Thereafter, there was a lack of potentiation of the fEPSP throughout the period of apnea as shown in Fig. 2A. In another animal, MK-801 was injected intravenously in order to assess the global effects of the blockade of NMDA receptors, since the drug passes through the blood–brain barrier (Kemp et al., 1987). After the injection of MK-801 (2 mg/kg in saline, i.v.) 15 min prior to the induction of apnea, there was no change in the amplitude of the fEPSP and apnea was no longer able to produce any potentiation of the fEPSP (data not shown).

    View all citing articles on Scopus
    View full text